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experienced a local recurrence at 5 months and 22 months, 
respectively (one of these patients developed a second local 
recurrence 3 years after the first recurrence). One patient 
developed a lung metastasis 17 months after diagnosis. All 
recurrent stage II patients were treated and are alive with no 
evidence of disease (NED). 
Of 41 stage III patients, a recurrence was experienced in 3 
patients (7%). All of these recurrences were in the lung and 
were experienced at 4 months, 5 months, and 7 months after 
diagnosis. 
One out of eleven patients (9%) with stage IV disease 
experienced a recurrence. This was a local recurrence 
experienced 4 months after diagnosis. None of the 8 patients 
with stage V disease experienced a recurrence. Risk of 
progression based on stage is shown in the table below. 
The median time to failure was 6 months from diagnosis. Of 
the eight total recurrences (including 2 local recurrences in a 
single patient), 6 were salvaged and currently have no 
evidence of disease. Two patients are alive with active 
disease. 
Progression-free survival was 89%. Sixty three of the 64 
patients are still alive, giving an overall survival of 98.4%. 
The single patient who died had stage IV disease at diagnosis 
and experienced a recurrence prior to death. 
 
Stage PFS (%) OS (%) 
I 100 100 
II 80 100 
III 93 100 
IV 91 91 




Conclusions: Children with Wilms tumor can have excellent 
long-term outcomes when managed per NWTS/COG 
protocols. After 11 years of median follow up, PFS and OS 
were both excellent at 89% and 98.4%, respectively. 
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Purpose/Objective: To analyze the epidemiological 
characteristics of paediatric patients with Ewing's Sarcoma 
(ES) and assess the outcome (overall survival [OS] and disease 
free survival [DFS]) as well as potential prognostic factors 
associated with survival after the multidisciplinary 
treatment.  
Materials and Methods: Retrospective study of paediatric 
patients with ES treated during the period 1979-2014. SPSS 
19.0 was used for statistical analysis and Kaplan-Meier's 
method for the analysis of survival. The potential risk factors 
were assessed using univariate and multivariate analyses. 
Results: During the last 35 years, 102 patients were treated 
at our Institution. Male patients were 55.8% and the median 
age was 10.5 years (range 2-19). The pain was the most 
common symptom at initial presentation. Non-axial location 
was observed in 62.8% of patients and non-metastatic or 
multicentric disease in 83.3%. The median time between the 
onset of symptoms and the date of diagnosis was 3.07 months 
(range: 0.1- 36.5 months). 68.7% received surgery, 49% 
radiotherapy (with radical intention, before or after surgery) 
and 25.5 % hematopoietic stem cell transplantation. The 2 
and 5-years OS was 81 % and 57 %, respectively. Two and five 
years DFS was 68% and 54%, respectively. Local recurrence 
occurred in 11.8 % and distant relapse in 36.2 % of patients. 
Secondary malignancies occurred in 5% of patients (2 acute 
myeloblastic leukemia, 2 myelodysplastic syndromes and one 
pleomorphic sarcoma). Risk factors for OS observed in the 
univariate analysis were: an erythrocyte sedimentation rate 
at diagnosis > median (Median 43; HR: 4.42, p = 0.02), the 
lack of surgery (HR 1.97, p = 0.024), poor pathological 
responder (> 10% viable tumor) to induction chemotherapy 
(HR 2.88, p = 0.012), the use of cobalt units vs. linear 
accelerators (HR 2.93, p = 0.009) and the response to 
multidisciplinary treatment (progression versus rest of 
responses; HR 6.52, p <0.001). In multivariate analysis only 
the radiotherapy units (HR 4,21, p = 0,030) and the response 
to treatment (Response vs progression: HR 0,10, p < 0,001) 
retained statistically significance. 
Conclusions: Our results suggest that paediatric patients with 
ES who have a good response to the multidisciplinary 
treatment or those treated with linear accelerators vs cobalt 
units have a lower risk of mortality. Therefore, it seems that 
technological development has contributed to improve the 
survival in these patients.  
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Purpose/Objective: Use of stereotactic radiotherapy (SRT) is 
increasingly common practice in radiation therapy for the 
adult population, but there is little consensus regarding its 
application in pediatrics. We evaluated clinical patterns of 
pediatric SRT practice through an international pediatrics 
consortium comprised of institutions using either photon or 
proton radiotherapy. 
Materials and Methods: Seven international institutions with 
dedicated pediatric expertise completed a 124-item survey 
evaluating patterns of SRT use in definitive and palliative 
radiation therapy for patients ≤21 years old. One institution 
uses proton SRT for children and all others use photon 
therapy. Descriptive statistics including frequencies of SRT 
use and median doses and margins applied with and without 
SRT by institution and treatment site were calculated. 
Results: Across institutions, 71% reported utilizing SRT in 
pediatrics. Definitions of SRT varied by institution, with 
providers specifying that a minimum fractional dose ranging 
from 1.80-6 Gy with delivery in a maximum of 5-33 fractions 
could be classified as SRT. A median of 11.2 (range 0-13) 
pediatric patients are treated with SRT of any fractionation 
regimen annually across institutions, with median 7 (range 0-
10) treated with hypofractionated SRT (hSRT). hSRT is used in 
an average of 1% of brain, 17% of spine, 21% of other bone, 
and <1% of abdomen or pelvis, head and neck, lung, and liver 
radiotherapy cases across institutions. Half of the cases 
treated with hSRT are performed with palliative intent. 
Ranges of total dose reported for hSRT are 12-30 Gy in 1-5 
fractions for brain, 14-40 Gy in 1-5 fractions for spine and 
other bone, 10-30 Gy in 2-5 fractions for abdomen or pelvis, 
and 10-50 Gy in 1-5 fractions for lung sites. Although 
immobilization and simulation procedures vary by treatment 
site and institution, daily IGRT is utilized in nearly 100% of 
cases. The median total GTV-PTV margins for SRT vs. non-SRT 
plans are 0.2 vs.1.4 cm for brain, 0.15 vs. 1.5 cm for spine, 
0.35 vs. 1.5 cm for other bone, 0.5 vs. 2 cm for abdomen or 
pelvis, 0.3 vs. 1.5 cm for head and neck, 0.5 vs. 1.7 cm for 
lung, and 0.5 vs. 2 cm for liver sites, respectively. 
Conclusions: Use of SRT in children was prevalent at all 
consortium institutions, with variation in site-specific 
definitions and procedures utilized for this technique. GTV-
PTV margins used for SRT are up to 4 times smaller than for 
non-SRT planning, highlighting the utility of this approach in 
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Purpose/Objective: Due to population ageing, there is an 
increased incidence of cancers, particullary for those with a 
long latency period, such as urothelial bladder carcinoma. 
Radiochemotherapy, in our area, is indicated as a first 
curative approach for very elderly patients with good general 
condition.  
Materials and Methods: We assessed the outcomes of 41 
consecutively patients at a mean age of 82 years at time of 
diagnosis, treated with radiotherapy (+/- chemotherapy) 
following TURBT from February 2010 to January 2014. 
Patients were T2-3 N0-1 M0 high grade urothelial bladder 
cancer. All patients had at least a Karnofsky index of 90% 
and/or a Barthel scale of at least 95. A prior TURB (maximal 
or flattened) was performed in all patients. Hydronephrosis 
was present in only 19% of patients, in situ in 20% and a 61% 
of tumors were <5cm. 
All patients received radiotherapy to a median dose of 60Gy 
(40-68Gy) in a normofractionated schedule, delivered with 
3D-CRT and high energy photons. Chemohterapy was 
delivered to 35 patients in different schedules (concurrent 
carboplatin 47%, neoadjuvant cisplatin-gemzitabine 25%, and 
concurrent cisplatin 6%). 
Results: At median follow-up 30(5-53) months for survivors, 
17 patients have dead. 41% of patients are alive more than 10 
months, one third (34%) with no signs of any type of 
recurrence, and a 64.2% having no signs of local progression, 
either on cytology, cystoscopy, echography or CT scan. 
Eleven deaths were disease-related. Overall median survival 
was 13 months. 1,2 and 3- year overall survival were 73%, 
54% and 49% respectively. 
By comparing patient, tumor and treatment characteristics of 
patients living more than 10 months vs dead patients, we 
only found a tend to statistical difference favouring the 
presence of a previous superficial tumor in alive patients 
(31.5% vs 6%, p= 0.07).  
Acute tolerance was well, with only one G3 hematuria and a 
patient with haematologic toxicity chemotherapy-related 
that both need to interrupt their RT. Main acute toxicity 
were dysuria (56.1%) followed by pollakiuria (53.7%), and 
diarrhea (36.6%). A 28.6% of women had also symptoms of 
